October 2007

Contents

Editorial

Volume 8 Number 10 October 2007

Conference reports

BHIVA Autumn conference, 11-12 October 2007, London

Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3

Antiretrovirals

Atripla approved in Europe as switch option for suppressed patients

Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients

Paediatric formulation of fosamprenavir approved in Europe

Raltegravir approved in the US

EMEA recommends reinstating license for Roches nelfinavir

Roche withdraw application for Biojector needle-free option for T-20

Treatment strategies

Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999

Treatment access

Donor governments pledge record amounts to the Global Fund

Survival of HIV-positive IDUs in the era of HAART

Women's health

Antiretroviral drug exposure in the female genital tract

Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Womens Interagency HIV Study

Pregnancy

Pregnancy shows a positive impact on HIV disease progression

African infants CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine prophylaxis

Low rates of mother to child transmission in the DREAM and MTCT-Plus programmes

Paediatric care

Risk factors for early mortality for children receiving divided adult fixed dose combination tablets in Malawi

Hepatitis coinfection

Risk of antibody negative HCV infection in four US HIV cohorts: risk linked to IDU, elevated ALT and low CD4 count

Vaccines and microbicides

Merck HIV vaccine trial halted by DSMB for lack of efficacy

On the web

Free full text articles

Conference abstracts and presentations

PDFs

Volume 8 Number 10 October 2007 PDF